Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Su, W.-C.
Right arrow Articles by Tsao, C.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Su, W.-C.
Right arrow Articles by Tsao, C.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:562-567 (2000)
© 2000 Foundation for Promotion of Cancer Research

Comparison of In Vitro Growth-inhibitory Activity of Carboplatin and Cisplatin on Leukemic Cells and Hematopoietic Progenitors: the Myelosuppressive Activity of Carboplatin May Be Greater Than Its Antileukemic Effect

Wu-Chou Su1, Shu-Ling Chang1, Tsai-Yun Chen1, Jiann-Shiuh Chen2 and Chao-Jung Tsao1,+

1Division of Hematology/Oncology, Departments of Internal Medicine and 2Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan

Background: Carboplatin [cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II)] has been shown to be an active agent for acute myeloid leukemia. This second-generation platinum drug has less nephrotoxicity and ototoxicity but more myelotoxicity than does the first-generation platinum drug cisplatin. The study was designed to elucidate whether their myelosuppressive activities equal their antileukemic effects.

Methods: Cisplatin and carboplatin were used to treat four leukemic cell lines (CEM, HL60, K562 and U937), blast cells from 10 leukemic patients and hematopoietic progenitors from five umbilical cord blood samples.

Results: The mean IC50 of leukemic cell lines was 0.4 and 6.2 µg/ml, the mean IC50 of patients’ leukemic blasts was 2.0 and 22.4 µg/ml and the mean IC50 of hematopoietic progenitors (BFU-E, CFU-E and CFU-GM) was 1.8 and 1.7 µg/ml for cisplatin and carboplatin, respectively.

Conclusions: Carboplatin required a 10 times higher drug concentration than cisplatin to induce a similar degree of growth inhibition on leukemic cells. However, the hematopoietic progenitors responded equally to cisplatin and carboplatin at the same drug concentration. The results suggest that the myelosuppressive activity of carboplatin is greater than its antileukemic effect.

+ For reprints and all correspondence: Wu-Chou Su, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 70428, Taiwan. E-mail: sunnysu@mail.ncku.edu.tw


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.